Alessandro Pocai

Alessandro Pocai

Auto-generated profile, based on publicly available information

Alessandro Pocai

Cardiovascular & Metabolism Johnson & Johnson Innovative Medicines Spring House Pennsylvania USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Cell Reports
Verified
Journal Article
Open access
LMLorella Marselli
Lorella Marselli
APAnthony Piron
Anthony Piron
MSMara Suleiman
Mara Suleiman
MCMaikel L. Colli
Maikel L. Colli
XYXiaoyan Yi
Xiaoyan Yi
PMPiero Marchetti
Piero Marchetti
Pancreatic β cell failure is key to type 2 diabetes (T2D) onset and progression. Here, we assess whether human β cell dysfunction induced by metabolic stress is reversible, evaluate the molecular pathways underlying persistent or transient damage, and explore the relationships with T2D islet traits. Twenty-six islet preparations are exposed to several lipotoxic/glucotoxic conditions, some of which impair insulin release, depending on stressor type, concentration, and combination. The reversal of dysfunction occurs after washout for some, although not all, of the lipoglucotoxic insults. Islet transcriptomes assessed by RNA sequencing and expression quantitative trait loci (eQTL) analysis identify specific pathways underlying β cell failure and recovery. Comparison of a large number of human T2D islet transcriptomes with those of persistent or reversible β cell lipoglucotoxicity show shared gene expression signatures. The identification of mechanisms associated with human β cell dysfunction and recovery and their overlap with T2D islet traits provide insights into T2D pathogenesis, fostering the development of improved β cell-targeted therapeutic strategies.

10 October 2025 in Science Advances
Verified
Journal Article
Open access
MSMara Suleiman
Mara Suleiman
TSToshiaki Sawatani
Toshiaki Sawatani
MTMarta Tesi
Marta Tesi
XYXiaoyan Yi
Xiaoyan Yi
TPTheodora Papadopoulou
Theodora Papadopoulou
LMLorella Marselli
Lorella Marselli
Remission of type 2 diabetes (T2D) can occur after hypocaloric diet, bariatric surgery, or pharmacological treatments and associates with improved β cell function. Here, we studied islets from nondiabetic ( n = 15) and T2D ( n = 21) donors. We examined whether T2D β cell dysfunction can be rescued, charted the underlying molecular mechanisms by RNA sequencing, and mined transcriptomes for drug targets. Glucose responsiveness of T2D β cells improved in 60% of preparations after 3-day culture in euglycemic conditions. This was accompanied by changes in expression of >400 genes involved in functional or inflammatory pathways. Drug repurposing and target identification analyses predicted chemical and genetic hits, including JAK inhibitors, which were validated in a β cell line, human islets, and db/db mice. Therefore, defective β cell glucose responsiveness in T2D can recover, demonstrating β cell functional plasticity. The recovery associates with transcriptomic traits, pointing to targetable defects to induce T2D remission.

8 December 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BRBrian Rady
Brian Rady
TNTakahiro Nishio
Takahiro Nishio
DDDebanjan Dhar
Debanjan Dhar
XLXiao Liu
Xiao Liu
MEMark Erion
Mark Erion
APAlessandro Pocai
Alessandro Pocai
Non-alcoholic steatohepatitis (NASH) results, in part, from the interaction of metabolic derangements with predisposing genetic variants, leading to liver-related complications and mortality. The strongest genetic determinant is a highly prevalent missense variant in patatin-like phospholipase domain-containing protein 3 (PNPLA3 p.I148M). In human liver hepatocytes PNPLA3 localizes to the surface of lipid droplets where the mutant form is believed to enhance lipid accumulation and release of pro-inflammatory cytokines. Less is known about the role of PNPLA3 in hepatic stellate cells (HSCs). Here we characterized HSC obtained from patients carrying the wild type (n = 8 C/C) and the heterozygous (n = 6, C/G) or homozygous (n = 6, G/G) PNPLA3 I148M and investigated the effect of genotype and PNPLA3 downregulation on baseline and TGF-β-stimulated fibrotic gene expression. HSCs from all genotypes showed comparable baseline levels of PNPLA3 and expression of the fibrotic genes α-SMA, COL1A1, TIMP1 and SMAD7. Treatment with TGF-β increased PNPLA3 expression in all 3 genotypes (~2-fold) and resulted in similar stimulation of the expression of several fibrogenic genes. In primary human HSCs carrying wild-type (WT) PNPLA3, siRNA treatment reduced PNPLA3 mRNA by 79% resulting in increased expression of α-SMA, Col1a1, TIMP1, and SMAD7 in cells stimulated with TGF-β. Similarly, knock-down of PNPLA3 in HSCs carrying either C/G or G/G genotypes resulted in potentiation of TGF-β induced expression of fibrotic genes. Knockdown of PNPLA3 did not impact fibrotic gene expression in the absence of TGF-β treatment. Together, these data indicate that the presence of the I148M PNPLA3 mutation in HSC has no effect on baseline activation and that downregulation of PNPLA3 exacerbates the fibrotic response irrespective of the genotype.


1 July 2026 in JCSM Communications
Verified
Journal Article
Open access
PDF file
APAlessandro Pocai
Alessandro Pocai
Heart failure with preserved ejection fraction (HFpEF) is increasingly understood as a systemic disorder of impaired energetics and metabolic inflammation rather than an isolated disease of cardiac structure or haemodynamics. Although cardiac abnormalities define the diagnosis, they do not explain the severity of exercise intolerance, fatigue and loss of physical function that dominate the clinical phenotype. Converging physiological, metabolic and clinical evidence identifies extracardiac mechanisms, particularly skeletal muscle dysfunction, as key determinants of disability in HFpEF. Recent studies have reported an association between expansion of epicardial adipose tissue (EAT) and skeletal muscle fatigability in HFpEF, independent of generalized obesity or body mass index. Strikingly, muscle endurance is disproportionately impaired relative to muscle mass or maximal strength, revealing a qualitative defect in muscle performance rather than classical sarcopenia. This dissociation, illustrated by preserved force generation alongside accelerated fatigue, implicates impaired mitochondrial oxidative capacity and reduced fatigue resistance as central contributors to functional limitation. In this review, we synthesize emerging evidence on skeletal muscle bioenergetics, mitochondrial dysfunction and adipose–muscle crosstalk to propose a myopenic phenotype as a unifying framework for HFpEF‐related disability. Myopenia, defined as clinically meaningful muscle dysfunction driven primarily by impaired muscle quality rather than overt muscle wasting, captures a pattern of wasting biology without obligatory loss of muscle mass. Within this framework, EAT is conceptualized as a metabolically active visceral fat depot that may amplify systemic inflammation and disrupt skeletal muscle oxidative metabolism through an integrated adipo‐muscular axis. By shifting emphasis from cardiac mechanics and muscle quantity towards muscle endurance, metabolic efficiency and inter‐organ energetic signalling, this framework aligns HFpEF with systems‐level paradigms underlying cachexia, metabolic ageing and chronic organ failure. Framing HFpEF as a clinically relevant myopenic state supports muscle‐centric outcome measures and integrated therapeutic strategies aimed at correcting multisystem energetic failure and preventing loss of physical function.